RenovoRx, Inc.
RNXT evidence brief
What we can confirm
- BioSniper Score:
- 7.0 / 10
- Market Cap:
- $79.4M
- Lead Asset:
- renovogem (Phase 3)
What it means
What to watch
Prepared research question
What matters most for RNXT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RNXT
RenovoRx, Inc. (RNXT) is a clinical-stage life sciences company developing targeted oncology therapies using its patented Trans-Arterial Micro-Perfusion (TAMP) platform and RenovoCath local drug-delivery device, with a lead product candidate (IAG) in a Phase III trial for pancreatic cancer and early commercial revenue from standalone device sales.
Key risk: No approved drug-device combo
BioSniper Score
Based on 4 of 6 signals
Market Cap
$79.4M
Cash Runway
—
Lead Asset
renovogem (Phase 3)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for RenovoRx, Inc..
RenovoRx, Inc. (RNXT) is a clinical-stage life sciences company developing targeted oncology therapies using its patented Trans-Arterial Micro-Perfusion (TAMP) platform and RenovoCath local drug-delivery device, with a lead product candidate (IAG) in a Phase III trial for pancreatic cancer and early commercial revenue from standalone device sales.
- RenovoRx is a clinical-stage biopharmaceutical company with no approved drug/device combination products; its lead candidate IAG (intra-arterial gemcitabine via RenovoCath) is in Phase III TIGeR-PaC trial for locally advanced pancreatic cancer [sec_mda · as of 2026-05-14].
- RenovoCath, an FDA-cleared local drug-delivery device, generated $1.1 million in revenue in 2025, its first full year of commercialization [news · published 2026-03-30].
- As of June 30, 2026, the company reported cash and cash equivalents of $9.5 million, a net loss of $6.4 million for the first half of 2026, and an accumulated deficit of $67.8 million [sec_mda · as of 2026-08-13].
- The Phase III TIGeR-PaC trial is expected to complete enrollment by mid-2026, with final data anticipated in 2027 [news · published 2026-03-30].
- RenovoCath with gemcitabine received Orphan Drug Designation for pancreatic cancer and bile duct cancer, providing seven years of market exclusivity upon FDA approval [sec_mda · as of 2026-05-14].
What works
- RenovoCath generated $1.1 million in revenue in its first full year of commercialization, indicating early market traction [news · published 2026-03-30].
- The company's Phase III TIGeR-PaC trial is on track for enrollment completion by mid-2026, with final data expected in 2027, advancing its lead product candidate [news · published 2026-03-30].
- RenovoCath with gemcitabine has Orphan Drug Designation for pancreatic and bile duct cancers, which could provide market exclusivity upon approval [sec_mda · as of 2026-05-14].
- The company had $9.5 million in cash as of June 30, 2026, providing a runway to continue operations and clinical development [sec_mda · as of 2026-08-13].
What to weigh
- RenovoRx has no approved drug/device combination products and limited experience as a revenue-generating company, making its commercial prospects unproven and risky [sec · filed 2026-05-15].
- The company reported a net loss of $6.4 million for the first half of 2026 and an accumulated deficit of $67.8 million, with negative cash flow expected to continue [sec_mda · as of 2026-08-13].
- The Phase III TIGeR-PaC trial's failure would cause significant harm to the company, as it is the most advanced clinical study [sec_mda · as of 2026-05-15].
- Revenue from RenovoCath is still limited and may not offset expenses in the near term; the company expects to incur losses until regulatory approval or sufficient device sales materialize [sec_mda · as of 2026-03-30].
From the filings
Quoted directly from source documents.
RenovoRx has no approved drug/device combination products and limited commercial experience.
“We have no drug/device combination products approved for commercial sale. While we have commenced generating revenue from RenovoCath commercial sales, our operating history as a revenue-generating company remains limited, and the commercial prospects for our novel therapy platform (either as part of an approved drug/device combination product or whether sold as a standalone product) are unproven, uncertain and involve a substantial degree of risk.”
SEC filings · May 15, 2026
RenovoCath generated $1.1 million in revenue in 2025.
“RenovoCath ® Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization”
News · March 30, 2026
Cash and cash equivalents were $9.5 million as of June 30, 2026.
“As of June 30, 2026, the Company had cash and cash equivalents of approximately $ 9.5 million .”
SEC MD&A · August 13, 2026
Phase III TIGeR-PaC trial enrollment completion expected by mid-2026, final data in 2027.
“Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of 2026, and Final Data Anticipated in 2027”
News · March 30, 2026
Risks & what to watch (4)›
Key risks
- No approved drug-device combo — RenovoRx has no approved drug/device combination products; all candidates are in development and subject to regulatory risk [sec · filed 2026-05-15].
- Negative cash flow and losses — Net loss of $6.4M in H1 2026, accumulated deficit $67.8M; negative cash flow expected to continue [sec_mda · as of 2026-08-13].
- Dependence on Phase III trial — Failure of the TIGeR-PaC study would cause significant harm to the company [sec_mda · as of 2026-05-15].
- Limited commercial revenue — RenovoCath revenue is still small ($1.1M in 2025) and may not offset expenses in near term [news · published 2026-03-30].
What to watch
- Completion of Phase III TIGeR-PaC trial enrollment, expected by mid-2026 [news · published 2026-03-30].
- Final data from the TIGeR-PaC trial, anticipated in 2027 [news · published 2026-03-30].
- Growth in RenovoCath commercial revenue and its impact on cash burn [sec_mda · as of 2026-08-13].
- Any regulatory milestones or FDA interactions regarding IAG or RenovoCath [sec_mda · as of 2026-05-14].
Sources: News · SEC filings · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run RenovoRx, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available RenovoRx, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.28 · 0% dilution
Lead: Phase 3
1 candidate
No upcoming catalysts tracked
1 buy · 0 sells (180d)
Pipeline
Financials
Short Interest
as of May 22, 2026- % of float
- 1.2%
- Days to cover
- 1.6
- Shares short
- 505,892
- Daily short volume (May 20, 2026)
- 34.5%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RNXT short interestGovernance
Frequently asked questions
What is the AI investment thesis for RenovoRx, Inc.?
RenovoRx, Inc. (RNXT) is a clinical-stage life sciences company developing targeted oncology therapies using its patented Trans-Arterial Micro-Perfusion (TAMP) platform and RenovoCath local drug-delivery device, with a lead product candidate (IAG) in a Phase III trial for pancreatic cancer and early commercial revenue from standalone device sales.
What is RenovoRx, Inc.'s lead drug candidate?
RenovoRx, Inc.'s most advanced tracked candidate is renovogem (Phase 3) for Bile duct cancer (extrahepatic cholangiocarcinoma).
Who is the CEO of RenovoRx, Inc.?
Mr. Shaun R. Bagai is the chief executive officer of RenovoRx, Inc. (RNXT).
Where is RenovoRx, Inc. headquartered?
RenovoRx, Inc. (RNXT) is headquartered in Mountain View, CA, United States.
What therapeutic areas does RenovoRx, Inc. focus on?
RenovoRx, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.